Staidson Beijing Biopharma (300204) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Staidson Beijing Biopharma (300204) has a cash flow conversion efficiency ratio of -0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-39.18 Million ≈ $-5.73 Million USD) by net assets (CN¥859.70 Million ≈ $125.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Staidson Beijing Biopharma market cap and net worth for the company's overall valuation and market capitalisation.
Staidson Beijing Biopharma - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Staidson Beijing Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Staidson Beijing Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Staidson Beijing Biopharma ranked by their cash flow conversion efficiency. Explore how high is Staidson Beijing Biopharma's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Railway Construction Corporation Limited
F:4FF
|
0.045x |
|
Galapagos N.V.
AS:GLPG
|
-0.024x |
|
Dalian Huarui Heavy Industry Group Co Ltd
SHE:002204
|
-0.016x |
|
ICF International Inc
NASDAQ:ICFI
|
0.095x |
|
Compania Nationala de Transport al Energiei Electrice Transelectrica SA
RO:TEL
|
0.054x |
|
Fagron NV
BR:FAGR
|
0.073x |
|
Jiangsu Zhangjiagang Rural Commercial Bank Co Ltd
SHE:002839
|
0.253x |
|
Antin IP SA
PA:ANTIN
|
0.108x |
Annual Cash Flow Conversion Efficiency for Staidson Beijing Biopharma (2007–2025)
The table below shows the annual cash flow conversion efficiency of Staidson Beijing Biopharma from 2007 to 2025. View 300204 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥806.72 Million ≈ $118.05 Million |
CN¥-125.68 Million ≈ $-18.39 Million |
-0.156x | -124.28% |
| 2024-12-31 | CN¥916.76 Million ≈ $134.15 Million |
CN¥-63.68 Million ≈ $-9.32 Million |
-0.069x | +68.83% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.36 Million |
CN¥-227.47 Million ≈ $-33.29 Million |
-0.223x | -71.83% |
| 2022-12-31 | CN¥1.35 Billion ≈ $198.11 Million |
CN¥-175.60 Million ≈ $-25.70 Million |
-0.130x | -24.10% |
| 2021-12-31 | CN¥1.55 Billion ≈ $226.92 Million |
CN¥-162.07 Million ≈ $-23.72 Million |
-0.105x | -44.78% |
| 2020-12-31 | CN¥1.59 Billion ≈ $232.30 Million |
CN¥-114.60 Million ≈ $-16.77 Million |
-0.072x | -366.21% |
| 2019-12-31 | CN¥1.64 Billion ≈ $239.29 Million |
CN¥44.34 Million ≈ $6.49 Million |
0.027x | -59.63% |
| 2018-12-31 | CN¥2.46 Billion ≈ $359.66 Million |
CN¥165.08 Million ≈ $24.16 Million |
0.067x | -45.77% |
| 2017-12-31 | CN¥2.21 Billion ≈ $323.30 Million |
CN¥273.64 Million ≈ $40.04 Million |
0.124x | +11.78% |
| 2016-12-31 | CN¥1.92 Billion ≈ $280.70 Million |
CN¥212.55 Million ≈ $31.10 Million |
0.111x | -19.24% |
| 2015-12-31 | CN¥1.68 Billion ≈ $246.39 Million |
CN¥231.01 Million ≈ $33.80 Million |
0.137x | +0.44% |
| 2014-12-31 | CN¥1.51 Billion ≈ $221.60 Million |
CN¥206.85 Million ≈ $30.27 Million |
0.137x | +61.17% |
| 2013-12-31 | CN¥1.31 Billion ≈ $192.28 Million |
CN¥111.36 Million ≈ $16.30 Million |
0.085x | +16.61% |
| 2012-12-31 | CN¥1.24 Billion ≈ $181.57 Million |
CN¥90.19 Million ≈ $13.20 Million |
0.073x | -7.94% |
| 2011-12-31 | CN¥1.10 Billion ≈ $161.27 Million |
CN¥87.01 Million ≈ $12.73 Million |
0.079x | -79.46% |
| 2010-12-31 | CN¥166.23 Million ≈ $24.32 Million |
CN¥63.91 Million ≈ $9.35 Million |
0.384x | +8.64% |
| 2009-12-31 | CN¥119.72 Million ≈ $17.52 Million |
CN¥42.37 Million ≈ $6.20 Million |
0.354x | +36.99% |
| 2008-12-31 | CN¥62.82 Million ≈ $9.19 Million |
CN¥16.23 Million ≈ $2.37 Million |
0.258x | +61.81% |
| 2007-12-31 | CN¥33.87 Million ≈ $4.96 Million |
CN¥5.41 Million ≈ $791.30K |
0.160x | -- |
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respi… Read more